Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: results from the TEAMIIA study (BOOG2006-04)

Abstract Purpose In the adjuvant setting, specific adverse events(AEs) such as vasomotor symptoms (VMS) and musculoskeletal AEs are associated with relapse-free survival in aromatase inhibitor(AI)-treated patients. In the neoadjuvant setting, specific AEs may be associated with tumor response to AIs as well. Methods Between 2007 and 2012, 107 patients participated in the prospective TEAMIIA trial, a prospective, phase II trial investigating 6 months of neoadjuvant exemestane in patients with strongly ER-positive breast cancer. Radiological response (≥30% decrease in tumor size) was studied in relation to VMSs and MSAEs. Pearson’s Chi-Square tests and multivariate logistic regression analyses were used to evaluate of statistical significance (p